TBPH Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

6 days ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

12 days ago - By: Benzinga - Mentions: EXK SVM PAAS PCAR ...

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

12 days ago - By: Benzinga - Mentions: DCGO HTCR EXK ATMV ...

Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

17 days ago - By: Theravance Biopharma

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

3 months ago - By: The Motley Fool

Theravance Sales Jump 83 Percent

19 days ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

2 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

3 months ago - By: Zacks Investment Research - Mentions: GSK CRMD KNSA

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

3 months ago - By: Zacks Investment Research - Mentions: MGX

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Zacks Investment Research - Mentions: AKBA

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2

3 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

3 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Participate in an Upcoming Investor Conference

4 months ago - By: Zacks Investment Research - Mentions: CPRX ALDX LRMR ZVRA

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

4 months ago - By: Yahoo Finance - Mentions: VTRS

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma

4 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

5 months ago - By: Theravance Biopharma, Inc. - Mentions: GSK

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

6 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Participate in an Upcoming Investor Conference

6 months ago - By: Yahoo Finance - Mentions: JPM GS MS MRX ...

Digital health company Omada files for US IPO

6 months ago - By: Zacks Investment Research - Mentions: GSK ANIP VTRS

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y

6 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

6 months ago - By: Zacks Investment Research - Mentions: MDWD

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: Zacks Investment Research - Mentions: RIGL

Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates

6 months ago - By: Theravance Biopharma, Inc.

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

6 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

7 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

7 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Participate in an Upcoming Investor Conference

7 months ago - By: Theravance Biopharma, Inc.

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

8 months ago - By: Theravance Biopharma, Inc.

THERAVANCE BIOPHARMA INC (TBPH) Stock News

TBPH Latest News, Press Relases and Analysis

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

Theravance Sales Jump 83 Percent

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

Theravance Biopharma to Participate in an Upcoming Investor Conference

Digital health company Omada files for US IPO

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results